<table id="ID83" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="36%"></col>
<col width="64%"></col>
<tbody>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Interacting </content>
<content stylecode="bold">Drug </content>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Interaction </content>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Antacids, sucralfate, multivitamins, and other products containing multivalent cations <br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Moxifloxacin absorption is decreased. Administer moxifloxacin hydrochloride tablet at least 4 hours before or 8 hours after these products. (2.2, 7.1, 12.3, 17.2) <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Warfarin <br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Anticoagulant effect of warfarin may be enhanced. Monitor prothrombin time/INR, watch for bleeding. (6.4, 7.2, 12.3) <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Class IA and Class III antiarrhythmics: <br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Proarrhythmic effect may be enhanced. Avoid concomitant use. (5.3, 7.4) <br/>
</td>
</tr>
</tbody>
</table>